Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average: 2022-2024

Historic Equity Average for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Dec 2024 value amounting to $438.6 million.

  • Kiniksa Pharmaceuticals International's Equity Average rose 18.15% to $515.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.2 million, marking a year-over-year increase of 18.15%. This contributed to the annual value of $438.6 million for FY2024, which is 5.06% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Equity Average stood at $438.6 million for FY2024, which was up 5.06% from $417.5 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Equity Average peaked at $438.6 million during FY2024, and registered a low of $290.6 million during FY2022.
  • Its 3-year average for Equity Average is $382.2 million, with a median of $417.5 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Equity Average shows a peak YoY soared of 43.67% (in 2023) over the last 5 years.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's Equity Average (Yearly) stood at $290.6 million in 2022, then skyrocketed by 43.67% to $417.5 million in 2023, then increased by 5.06% to $438.6 million in 2024.